Skip to main content

MetaVia Inc.

corporate_fare Company Profile

MetaVia Inc.

MTVA·NASDAQ·Life Sciences·CIK 0001638287

We are a clinical-stage biotechnology company focused primarily on developing new medicines to treat heart and metabolism-related diseases. We have two main programs targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Our key product candidate, Vanoglipel (DA-1241), is a novel GPR119 agonist. It is being developed as a potential standalone or combination treatment for both MASH and Type 2 Diabetes Mellitus (T2DM). Vanoglipel (DA-1241) works by activating GPR119 in the gut, which releases important gut peptides like glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY (PYY). These peptides are involved in glucose metabolism, lipid metabolism, and weight loss. Preclinical studies have shown Vanoglipel (DA-1241) has positive effects on glucose, lipid profiles, and liver inflammation. In Phase 1a and 1b human clinical trials, Vanoglipel (DA-1241) was well tolerated in healthy volunteers and individuals with T2DM. We started a Phase 2a clinical trial in 2023 to understand its mechanism of action and effectiveness for MASH and to observe trends for T2DM. This was the first human MASH clinical trial for Vanoglipel (DA-1241). We completed the last patient last visit for this trial in November 2024. In December 2024, we announced positive initial 16-week results from the two-part Phase 2a clinical trial in patients with presumed MASH. We presented these initial 16-week results at the European Association for the Study of the Liver (EASL) 2025 in May 2025. In November 2025, we presented further analysis on glucose control in prediabetes and diabetes subjects, along with additional data on inflammation and lipid profiles, at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. We expect to finalize the Clinical Study Report (CSR) for the Phase 2a clinical trial in the first half of 2026.

MetaVia Inc. (NASDAQ:MTVA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 37 items for MTVA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for MTVA spans 8-K, 10-Q, 424B5.

Recent high-impact activity:

  • MetaVia Hit With Nasdaq Deficiency Notice After Equity Falls Below $2.5M
  • MetaVia's DA-1726 Matches Retatrutide Weight Loss With Less Appetite Suppression in Preclinical Study
  • MetaVia 10-Q: $8.8M Cash Into 1Q 2027, $13.8M Nine-Month Loss, Going Concern Stands
  • MetaVia Q3: $8.8M Cash Into 1Q 2027, Net Loss $4.6M, Phase 2 MetALD Set for 2H 2027
  • DA-1726 Cuts Liver Fat 68.1% Placebo-Adjusted in Interim Phase 1 Data

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$12.97M
Diluted EPS
-$7.35
Op. Cash Flow
-$15.7M
Free Cash Flow
-$15.7M
Operating Income
-$13.71M
Cash & Equivalents
$10.28M
Debt / Equity
0.00×
Shares Outstanding
2.31M sh
Source: 10-K · filed 2026-03-26 · accession 0001104659-26-034911

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 56,090 shares in MTVA as of the October 30, 2026 settlement, a 43.2% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 21.5% of MTVA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)56,090 shares as of October 30, 2026
Change vs prior period▼ 43.2%
Days to cover1.00 at avg daily volume of 70,460
Daily short volume (FINRA facilities)21.5% of 19,517 shares on November 20, 2026
5-day average short volume39.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for MTVA, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.

1 recent capital raiseATM program

ATM Program Expanded · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with M →
$1.05 +3.96% today
52-week range · as of 2026-11-18 $0.9661 – $13.42
Market cap
$6.81M
Volume
39.5K (0.3× avg)
3-mo avg 151.8K
Live data · 2026-11-21 18:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MTVA - Latest Insights

MTVA
Nov 18, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.23
Real-time Price: $1.05 info
Change: -$0.180 (-15%) info
Market Cap: $6.81M info
MTVA
Nov 16, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.27
Real-time Price: $1.05 info
Change: -$0.220 (-17%) info
Market Cap: $6.81M info
MTVA
Nov 13, 2026, 8:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.05 info
Change: -$0.350 (-25%) info
Market Cap: $6.81M info
MTVA
Nov 13, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.05 info
Change: -$0.350 (-25%) info
Market Cap: $6.81M info
MTVA
Nov 13, 2026, 8:31 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.05 info
Change: -$0.350 (-25%) info
Market Cap: $6.81M info
MTVA
Nov 12, 2026, 8:41 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.05 info
Change: -$0.460 (-30%) info
Market Cap: $6.81M info
MTVA
Nov 05, 2026, 9:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.32
Real-time Price: $1.05 info
Change: -$0.2693 (-20%) info
Market Cap: $6.81M info
MTVA
Aug 06, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.45
Real-time Price: $1.05 info
Change: -$0.400 (-28%) info
Market Cap: $6.81M info
MTVA
Jul 09, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.59
Real-time Price: $1.05 info
Change: -$0.5385 (-34%) info
Market Cap: $6.81M info
MTVA
Jul 02, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.42
Real-time Price: $1.05 info
Change: -$0.370 (-26%) info
Market Cap: $6.81M info
MTVA
Jul 02, 2026, 4:05 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.48
Real-time Price: $1.05 info
Change: -$0.430 (-29%) info
Market Cap: $6.81M info
MTVA
Jun 08, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.22
Real-time Price: $1.05 info
Change: -$1.17 (-53%) info
Market Cap: $6.81M info
MTVA
Jun 08, 2026, 9:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $2.22
Real-time Price: $1.05 info
Change: -$1.17 (-53%) info
Market Cap: $6.81M info
MTVA
Jun 08, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.21
Real-time Price: $1.05 info
Change: -$1.16 (-52%) info
Market Cap: $6.81M info
MTVA
May 27, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.63
Real-time Price: $1.05 info
Change: -$1.58 (-60%) info
Market Cap: $6.81M info
MTVA
May 18, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $1.05 info
Change: -$0.075 (-7%) info
Market Cap: $6.81M info
MTVA
May 14, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.05 info
Change: -$0.140 (-12%) info
Market Cap: $6.81M info
MTVA
May 14, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.19
Real-time Price: $1.05 info
Change: -$0.140 (-12%) info
Market Cap: $6.81M info
MTVA
May 14, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.19
Real-time Price: $1.05 info
Change: -$0.140 (-12%) info
Market Cap: $6.81M info
MTVA
May 11, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.11
Real-time Price: $1.05 info
Change: -$0.060 (-5%) info
Market Cap: $6.81M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets